Literature DB >> 7371363

Dependence liability of two antidiarrheals, nufenoxole and loperamide.

A Korey, D H Zilm, E M Sellers.   

Abstract

We compared the dependence liabilities of therapeutic doses of nufenoxole and loperamide. Ten subjects received 10 mg nufenoxole every 12 hr for 10 days, and 9 others received 4 mg loperamide every 12 hr for 10 days. On the eighth day of drug a sensitive single-blind intravenous naloxone challenge was used to assess dependence liability. After 0.2, 0.4, and 0.6 mg naloxone, pupillary constriction (0.618 to 0.540 cm, p less than 0.005) was measured in subjects receiving nufenoxole, whereas slight dilation (0.596 to 0.622 cm, p less than 0.05) was observed in those receiving loperamide. Trapezius electromyogram activity decreased by 30% for nufenoxole and 12% for loperamide. There were slight decreases in core and skin temperatures (0.06 degrees to 0.12 degrees) in both groups, partly attributable to experimental conditions. Changes in physiologic measurements after naloxone were similar in both groups and not of sufficient importance to suggest physical dependence liability for either loperamide or nufenoxole at the doses used.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7371363     DOI: 10.1038/clpt.1980.93

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Loperamide dependence and abuse.

Authors:  Ryan MacDonald; Jason Heiner; Joshua Villarreal; Jared Strote
Journal:  BMJ Case Rep       Date:  2015-05-02

2.  Nufenoxole, a new antidiarrhoeal agent, inhibits fluid secretion in the human jejunum.

Authors:  K J Moriarty; D D Rolston; M J Kelly; M Shield; M L Clark
Journal:  Gut       Date:  1985-01       Impact factor: 23.059

3.  Left Ventricular Regional Wall Motion Abnormality in the Setting of Acute Loperamide Overdose.

Authors:  Kasha Bornstein; Timothy Montrief; Mehruba Anwar Parris
Journal:  Clin Pract Cases Emerg Med       Date:  2019-07-01

4.  Local loperamide injection reduces mechanosensitivity of rat cutaneous, nociceptive C-fibers.

Authors:  Matthias Ringkamp; Michael Tal; Timothy V Hartke; Matthew Wooten; Alvin McKelvy; Brian P Turnquist; Yun Guan; Richard A Meyer; Srinivasa N Raja
Journal:  PLoS One       Date:  2012-07-25       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.